Novartis veteran Li Zhou has joined TxCell as the VP of cell engineering to oversee CAR-Treg programs for autoimmune and inflammation diseases.

The French Treg maverick, TxCell, has hoovered up more talent to pioneer its hybrid CAR-Treg therapies: Li Zhou will be the new Vice President of the company’s cell engineering division.

What we are doing here with CAR-Tregs to treat autoimmune diseases and transplantation-related disorders is truly unique. TxCell has strong Treg expertise as well as great partnerships with world-leading scientists. Everything is in place to rapidly build a solid cell engineering capacity,” Li Zhou said in a statement.

At TxCell, Li will lead the charge to discover and engineer new cell therapies for chronic inflammation and autoimmune diseases using the CAR-Treg analog of CAR-T therapy. These are generated by isolating Treg cells from the blood of patients and transducing them with CARs. The CAR-Treg products can then activate Treg cells by presenting proteins found in the inflamed regions of those afflicted with inflammatory and autoimmune diseases.

ADVERTISEMENT

Figure 1.

Figure 1.

Before joining TxCell, Li spent 6 years overseeing CAR-T therapy development at Novartis and bailed just a few months before the company folded its cell and gene therapy unit into the broader business. At that point, he moved on to become CSO at Shenzhen-based ZMKS International Cancer Therapy Biotechnologies.

Shortly thereafter, Li was poached by TxCell. Given his admirable performance at Novartis, where he oversaw CAR-T programs that have already had some clinical success, we have no doubt that Li will go on to do great things for TxCell.

This hiring move was the latest in a string at TxCell as it marshalls its immuno-oncology campaign in the competition against the likes of Juno, Kite, and Cellectis, the most successful biotech in France. The company recently hired Biogen SVP Olivier Danos as a board member in August, and it has packed a scientific advisory board with immunology experts. The CEO, Stephane Boissel, had more to say about the company’s progress in our panel at Refresh last summer – check out what he has to say on the development of CAR-T!


Featured Image: PORTRAIT IMAGES ASIA BY NONWARIT/shutterstock.com
Figure 1: iQoncept/shutterstock.com

Previous post

Meet the first Biotech to jump on Autophagy after this years' Nobel Prize

Next post

How can Cultured Meat solve World Hunger and Global Warming?

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.